In addition, it could be hypothesized that some of the association between the use of prolactin-increasing antipsychotics and breast cancer is due to more frequent contact with health care professionals and the health care system as a whole among women receiving an antipsychotic, whether with a pharmacist or a prescriber, resulting in an increased likelihood of being screened for breast cancer compared with women with schizophrenia but not receiving an antipsychotic. The gene discussed is PRL; the disease is schizophrenia.